Median Technologies weighs a split between its cash flow and its AI

On September 10th Median Technologies, a French medical-imaging firm, posted the sort of notice investors scroll past: its calendar for the rest of the year, with half-year results due on October 29th. Hardly news. Yet the date carries unexpected weight. Eight days earlier the board announced a strategic review committee weighing a separation of the company's two businesses, and the possible listing of one of them in America, to "unlock intrinsic value". A dry corporate schedule now doubles as the first milestone of a possible restructure.

The reason is that Median is two quite different companies sharing a single listed shell, and the market prices the pair at a compromise that suits neither. The first, iCRO, is a service business that runs and analyses the medical imaging for pharmaceutical companies' oncology drug trials. It is the entire source of revenue — €11.8m in the first half of 2026, up 4.4% on a year earlier — and its €82.4m order backlog gives it roughly two years of work in sight. It is also, for a growth stock, almost inert: full-year revenue rose just 2.2% in 2025, though the order book's 15.6% growth over the past year hints at acceleration to come.

The second business, eyonis, is why anyone owns the stock at all. It is a suite of AI software meant to spot early cancers, built around eyonis Lung Cancer Screening, which reads CT scans for suspicious nodules. In the past eight months it has passed the two regulatory gates that matter: clearance from America's Food and Drug Administration in February, and a European CE mark in July. It has, as yet, sold nothing.

Getting a diagnostic through regulators is the expensive prelude to a medicine's life, and Median's balance sheet shows how a small European firm finances such a bet. A €50m share issue completed in June bulked its cash to €60.8m; a €37.5m facility from the European Investment Bank and a stack of warrants, exercisable at €2.39 a share, stand ready to supply more. The warrant holders and the state-backed lender hold claims that rank ahead of ordinary shareholders, who are repeatedly asked to fund a product that has yet to earn its first euro.

Approvals do not equal adoption. eyonis's route to income runs through reimbursement — it secured a United States payment code worth about $650 per procedure — and through distributors: a commercial agreement with Tempus, an American AI-diagnostics firm, and a partnership with Olea Medical, part of Canon. Median targets its first paying sites in America this quarter and its first revenue by year-end. Whether it converts those agreements into money is the test that the October figures now frame.

That is why the calendar overlaps so awkwardly with the corporate restructure. Median's board insists the market undervalues the company, and a sum-of-the-parts reading shows why it might chafe. The whole group is worth just over €200m — about nine times a revenue base that is barely growing — while the software that could genuinely compound sits trapped in an illiquid French micro-cap, priced in euros and all but invisible to American buyers. The review's stated options include splitting iCRO from the medical-device arm and listing the latter in the United States, where AI-diagnostics peers trade at multiples no Euronext-listed stock would command.

None of this is decided; the review could end in a shrug, and the accompanying R&D committee only underlines that the steering is still to be done. But the calendar states where the incentives point. iCRO is the steady earner that must keep funding the build-out; eyonis is the option that needs American capital to reach its own valuation. October 29th will show whether the services arm remains a reliable engine. The sharper question for shareholders is whether the machine that turns regulatory approval into revenue is built before the dilution paying for it erases the premium that a split is supposed to unlock — the familiar arithmetic of a company whose first sale still lies ahead, after a decade of development.